Akèy › Kansè pwostat › Utah › Salt Lake City
Etid klinik pou Kansè pwostat nan Salt Lake City, UT
15 etid pou Kansè pwostat ap chèche patisipan nan sit nan ak bò kote Salt Lake City (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Study of AR Suppression With Carotuximab in Metastatic, Castration-Resistant Prostate Canc
Ap rekriteFaz 2
- Huntsman Cancer Institute and Hospital, Salt Lake City
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Ap rekriteFaz 1
- University of Utah - Huntsman Cancer Institute, Salt Lake City
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Ap rekriteFaz 3
- LDS Hospital, Salt Lake City
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Ap rekriteFaz 3
- Huntsman Cancer Institute, Salt Lake City
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Ap rekriteFaz 3
- University of Utah Sugarhouse Health Center, Salt Lake City
- Huntsman Cancer Institute/University of Utah, Salt Lake City
- LDS Hospital, Salt Lake City
- ak 1 plis
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
Ap rekriteFaz 3
- Research Site, Salt Lake City
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Ap rekriteFaz 3
- Huntsman Cancer Institute/University of Utah, Salt Lake City
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
Ap rekriteFaz 1
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Ap rekriteFaz 2
- Huntsman Cancer Institute/University of Utah, Salt Lake City
Creatine Supplementation and Resistance Training to Preserve Muscle Mass and Attenuate Cancer Progression
Ap rekriteFaz 3
- Huntsman Cancer Institute, Salt Lake City
Multimodal Telerehabilitation of Rural Patients With Advanced Prostate Cancer
Ap rekrite
- Huntsman Cancer Institute at University of Utah, Salt Lake City
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Ap rekriteFaz 1/2
- START Center for Cancer Care - Mountain Region, Salt Lake City
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Salt Lake City
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Ap rekriteFaz 3
- University of Utah Sugarhouse Health Center, Salt Lake City
- Huntsman Cancer Institute/University of Utah, Salt Lake City
- George E Wahlen Department of Veterans Affairs Medical Center, Salt Lake City
Impact of Multimodal Telerehabilitation in Rural Patients With Metastatic Prostate Cancer
Ap rekrite
- University of Utah Huntsman Cancer Institute, Salt Lake City
Etid Kansè pwostat nan lòt vil
- New York City, NY103 etid
- Houston, TX76 etid
- Los Angeles, CA61 etid
- Boston, MA59 etid
- St. Louis, MO46 etid
- Chicago, IL45 etid
- San Francisco, CA45 etid
- Philadelphia, PA44 etid
- Baltimore, MD43 etid
- Nashville, TN43 etid
- Seattle, WA42 etid
- Washington, DC38 etid
Lòt etid nan Salt Lake City
- Kansè Poumon ki pa ti selil31 etid
- Kansè (tout kalite)27 etid
- Kansè nan tete27 etid
- Kansè kolorektal22 etid
- Kansè poumon21 etid
- Melanom21 etid
- Myelom Miltip21 etid
- Kansè Metastatik20 etid
- Kansè ovè19 etid
- Obèsite18 etid
- Leksemi mieloïd egi17 etid
- Ensifizyans kadyak17 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.